Drugs / Dual-Target Antigen-Selected CAR-NK
last change Feb 2026 re-read 3 minutes ago

Dual-Target Antigen-Selected CAR-NK

Developed for
acute myeloid leukemia · breast cancer · colorectal cancer · cutaneous melanoma · glioblastoma · liver cancer · non-Hodgkin lymphoma · non-small cell lung carcinoma
+3 more · ovarian cancer · pancreatic ductal adenocarcinoma · prostate cancer
Investigated by
Essen Biotech

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07410494 Feb 2026 → Dec 2027 expected acute myeloid leukemia, breast cancer, colorectal cancer, cutaneous melanoma +7 Essen Biotech Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Dual-Target Antigen-Selected CAR-NK ClinicalTrials.gov intervention name — accepted as the source's own label NCT07410494 ↗